Frank Joseph Daugherty

This profile gathers the share dealings of Frank Joseph Daugherty in Greenwich LifeSciences, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 29 September 2020 to 25 April 2022, the count stands at 5 filings.

Every open-market trade on record is a purchase: 5 purchases worth €72k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2022 alone, the filings show 2 purchases and no sales.

Half of the purchases are above €15k and half below. 5 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 26 April 2022: an open-market purchase of €15k, in Greenwich LifeSciences, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.